JP2023520216A5 - - Google Patents
Info
- Publication number
- JP2023520216A5 JP2023520216A5 JP2022559844A JP2022559844A JP2023520216A5 JP 2023520216 A5 JP2023520216 A5 JP 2023520216A5 JP 2022559844 A JP2022559844 A JP 2022559844A JP 2022559844 A JP2022559844 A JP 2022559844A JP 2023520216 A5 JP2023520216 A5 JP 2023520216A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- subject
- cdr
- light
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024137709A JP2024159821A (ja) | 2020-04-01 | 2024-08-19 | 過剰な遊離ｌｉｇｈｔに関与する方法及び治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003826P | 2020-04-01 | 2020-04-01 | |
| US63/003,826 | 2020-04-01 | ||
| US202063027127P | 2020-05-19 | 2020-05-19 | |
| US63/027,127 | 2020-05-19 | ||
| US202163133636P | 2021-01-04 | 2021-01-04 | |
| US63/133,636 | 2021-01-04 | ||
| PCT/US2021/025068 WO2021202649A2 (en) | 2020-04-01 | 2021-03-31 | Methods and treatment involving excess free light |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024137709A Division JP2024159821A (ja) | 2020-04-01 | 2024-08-19 | 過剰な遊離ｌｉｇｈｔに関与する方法及び治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023520216A JP2023520216A (ja) | 2023-05-16 |
| JP2023520216A5 true JP2023520216A5 (enExample) | 2023-11-27 |
| JP7542077B2 JP7542077B2 (ja) | 2024-08-29 |
Family
ID=77929895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022559844A Active JP7542077B2 (ja) | 2020-04-01 | 2021-03-31 | 過剰な遊離ｌｉｇｈｔに関与する方法及び治療 |
| JP2024137709A Pending JP2024159821A (ja) | 2020-04-01 | 2024-08-19 | 過剰な遊離ｌｉｇｈｔに関与する方法及び治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024137709A Pending JP2024159821A (ja) | 2020-04-01 | 2024-08-19 | 過剰な遊離ｌｉｇｈｔに関与する方法及び治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11708406B2 (enExample) |
| EP (1) | EP4126945B1 (enExample) |
| JP (2) | JP7542077B2 (enExample) |
| KR (2) | KR102703936B1 (enExample) |
| CN (2) | CN118818053A (enExample) |
| AU (1) | AU2021248833A1 (enExample) |
| BR (1) | BR112022019112A2 (enExample) |
| CA (1) | CA3173873A1 (enExample) |
| MX (1) | MX2022011811A (enExample) |
| TW (1) | TWI865759B (enExample) |
| WO (1) | WO2021202649A2 (enExample) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6140467A (en) | 1997-07-07 | 2000-10-31 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US7118742B2 (en) | 1997-07-07 | 2006-10-10 | La Jolla Institute For Allergy And Immunology | Ligand for herpes simplex virus entry mediator and methods of use |
| US6998108B1 (en) | 1997-07-07 | 2006-02-14 | La Jolla Institute For Allergy And Immunology | Antibodies to p30 polypeptides and methods making and using same |
| DE60143231D1 (de) | 2000-04-12 | 2010-11-18 | Jolla Inst Allergy Immunolog | Ligand des zelleintritt-vermittelnden Proteins von Herpes Simplex und Methoden zu dessen Verwendungen |
| WO2010006071A1 (en) | 2008-07-08 | 2010-01-14 | La Jolla Institute For Allergy And Immunology | Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use |
| US8349320B2 (en) | 2004-12-09 | 2013-01-08 | La Jolla Institute For Allergy And Immunology | Compositions and methods for modulating responses mediated or associated with BTLA activity |
| US8153123B2 (en) | 2004-12-09 | 2012-04-10 | La Jolla Institute For Allergy And Immunology | Method for restoring dendritic cell populations |
| SI2292663T1 (sl) * | 2006-08-28 | 2014-02-28 | Kyowa Hakko Kirin Co., Ltd | Antagonistična humana monoklonska protitelesa, specifična za humani LIGHT |
| AU2007290570C1 (en) | 2006-08-28 | 2013-08-15 | Kyowa Kirin Co., Ltd. | Antagonistic human LIGHT-specific human monoclonal antibodies |
| EP2160200B1 (en) | 2007-05-14 | 2013-07-10 | The University of Chicago | Antibody-LIGHT fusion products as cancer therapeutics |
| US20090136427A1 (en) | 2007-09-18 | 2009-05-28 | La Jolla Institute For Allergy And Immunology | LIGHT Inhibitors For Asthma, Lung and Airway Inflammation, Respiratory, Interstitial, Pulmonary and Fibrotic Disease Treatment |
| WO2010111180A1 (en) | 2009-03-24 | 2010-09-30 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against light and uses thereof |
| KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약 |
| WO2013148350A2 (en) | 2012-03-26 | 2013-10-03 | Sanofi | Anti-light antibody therapy for inflammatory bowel disease |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| EP2872646B1 (en) | 2012-07-12 | 2017-08-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| EP3094651B1 (en) | 2014-01-14 | 2020-03-11 | Kymab Limited | Anti-light antibodies |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| EP3730188B1 (en) * | 2015-08-21 | 2024-07-31 | The Children's Hospital of Philadelphia | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| US11312781B2 (en) * | 2018-01-24 | 2022-04-26 | Capella Bioscience Ltd. | Antigen binding molecules that bind LIGHT |
-
2021
- 2021-03-31 WO PCT/US2021/025068 patent/WO2021202649A2/en not_active Ceased
- 2021-03-31 AU AU2021248833A patent/AU2021248833A1/en active Pending
- 2021-03-31 CA CA3173873A patent/CA3173873A1/en active Pending
- 2021-03-31 KR KR1020227037145A patent/KR102703936B1/ko active Active
- 2021-03-31 MX MX2022011811A patent/MX2022011811A/es unknown
- 2021-03-31 CN CN202410576655.7A patent/CN118818053A/zh active Pending
- 2021-03-31 TW TW110112015A patent/TWI865759B/zh active
- 2021-03-31 EP EP21779221.7A patent/EP4126945B1/en active Active
- 2021-03-31 JP JP2022559844A patent/JP7542077B2/ja active Active
- 2021-03-31 BR BR112022019112A patent/BR112022019112A2/pt unknown
- 2021-03-31 CN CN202180025379.XA patent/CN115768791B/zh active Active
- 2021-03-31 KR KR1020247029419A patent/KR20240135067A/ko active Pending
- 2021-03-31 US US17/218,449 patent/US11708406B2/en active Active
-
2023
- 2023-06-05 US US18/329,069 patent/US12331107B2/en active Active
-
2024
- 2024-08-19 JP JP2024137709A patent/JP2024159821A/ja active Pending
-
2025
- 2025-05-09 US US19/203,608 patent/US20260085112A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3050901B1 (en) | Soluble human st-2 antibodies and assays | |
| JP2021176860A (ja) | 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）および抗体 | |
| CN111620945A (zh) | 一种抗新型冠状病毒的单克隆抗体或其衍生体 | |
| KR20130043168A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2018513116A5 (enExample) | ||
| FI3553084T3 (fi) | Anti-adrenomedulliinivasta-aine (ADM) tai anti-ADM-vasta-ainefragmentti tai anti-ADM-non-Ig-skaffoldi elimen toimintahäiriön tai elimen vajaatoiminnan ehkäisemiseksi tai pienentämiseksi kroonisen tai akuutin taudin tai akuutin tilan omaavassa potilaassa | |
| JP2004534513A5 (enExample) | ||
| US20200299378A1 (en) | Methods of treating diseases | |
| CN102740877B (zh) | 对源自hsp65的肽-6有特异性的人源化抗体及其方法和用途 | |
| CN118165106A (zh) | 抗犬il-31单克隆抗体及其应用 | |
| TWI868379B (zh) | 結合ｂ型肝炎病毒表面抗原的抗體及其應用 | |
| CN118702814A (zh) | 一种抗ngf单克隆抗体及其应用 | |
| JP2023520216A5 (enExample) | ||
| CN118085082A (zh) | 抗猫TNF-α单克隆抗体及其应用 | |
| TW202210511A (zh) | 涉及il-18抗體之方法及治療 | |
| US20220267428A1 (en) | BLOCKADE OF RGMb FOR TREATING INFLAMMATORY BOWEL DISEASE AND COLITIS | |
| JP2018024615A (ja) | Ｈｔｌｖ−１関連炎症性疾患を治療する医薬組成物 | |
| CN115768791B (zh) | 涉及过量游离light的方法和治疗 | |
| WO2020023619A2 (en) | Blood brain barrier selective antibodies and methods of use | |
| EP4710108A1 (en) | Mid-regional pro-adrenomedullin immunoassay with monoclonal antibodies | |
| CN120775039A (zh) | 可结合SFTSV的纳米抗体Nb3-18及其应用 | |
| CN120535615A (zh) | 可结合SFTSV的纳米抗体Nb3-26及其应用 | |
| WO2024038185A1 (en) | Method of selecting patients for treatment with an il-33 axis antagonist | |
| CN120535616A (zh) | 可结合SFTSV的纳米抗体NbG7-4及其应用 | |
| CN121108357A (zh) | 抗amhr2×cd3双特异性抗体及其制备和用途 |